Miki M
Gan No Rinsho. 1985 May;31(6 Suppl):664-9.
The clinical usefulness of PAP and PA as a tumor marker for the prostate cancer were discussed. The materials for this study were 1385 cases which contained 158 cases with prostatic carcinoma. The positive rate of serum PAP and PA were 77.7% and 94.1% in untreated prostatic carcinoma and 15.1% and 70.0% in benign prostatic hypertrophy using 3.0 ng/ml as an upper limit of normal controls of serum PAP and PA. The cut off level in serum PA should be discussed more. PA was not superior to PAP as a tumor marker in the series, but our results have suggested the simultaneous assay of serum PAP and PA is valuable in detection and following-up of prostate cancer.
讨论了前列腺酸性磷酸酶（PAP）和脯氨酸氨基肽酶（PA）作为前列腺癌肿瘤标志物的临床实用性。本研究的材料为1385例病例，其中包含158例前列腺癌患者。以血清PAP和PA正常对照上限3.0 ng/ml为标准，未经治疗的前列腺癌患者血清PAP和PA的阳性率分别为77.7%和94.1%，良性前列腺增生患者血清PAP和PA的阳性率分别为15.1%和70.0%。血清PA的临界值水平仍需进一步探讨。在本系列研究中，PA作为肿瘤标志物并不优于PAP，但我们的结果表明，同时检测血清PAP和PA对前列腺癌的检测和随访具有重要价值。
